2024 annual financial data
Inhibrx Biosciences 2024 Net margin
Direct answer
Net margin was 843,786%.
Operating income was -331,448,000 USD and net income was 1,687,572,000 USD.
Operating cash flow was -194,409,000 USD.
Get free Inhibrx Biosciences email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 200,000 USD
- Operating income
- -331,448,000 USD
- Net income
- 1,687,572,000 USD
- Operating cash flow
- -194,409,000 USD